Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Lactobacillus Acidophilus→

Lactobacillus Acidophilus Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
68333-16-4
Molecular formula
Not available
Molecular weight
Not available
Drug class
Probiotic microorganismlactic-acid-producing Gram-positive bacterium
Mechanism of action
Potential probiotic effects include lactic-acid production, modulation of intestinal microbiota, pathogen exclusion and interaction with epithelial-barrier and immune pathways. These actions vary by strain; findings for one strain should not be generalised to all Lactobacillus acidophilus products.
Indications / reported uses
  • Used in oral probiotic and dietary-supplement products intended to support gastrointestinal microbiota; clinical indications and evidence must be assessed at the specific strain and product level.

Sources: https://doi.usp.org/USPNF/USPNF_M16355_02_01.html · https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lactobacillus-acidophilus · https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/ · https://ajp.amjpathol.org/article/S0002-9440%2821%2900048-1/fulltext · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Lactobacillus Acidophilus Environmental Risk Assessment (ERA) (the Lactobacillus Acidophilus ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.